WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000059525) USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/059525    International Application No.:    PCT/US2000/009240
Publication Date: 12.10.2000 International Filing Date: 05.04.2000
Chapter 2 Demand Filed:    30.10.2000    
IPC:
A61K 38/18 (2006.01), C07K 16/32 (2006.01)
Applicants: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US)
Inventors: HUANG, Xiaojian; (US).
STEWART, Timothy, Andrew; (US)
Agent: MARSCHANG, Diane, L.; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990 (US).
KIDDLE, Simon, J.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB)
Priority Data:
60/128,017 06.04.1999 US
Title (EN) USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES
(FR) UTILISATION DE LIGANDS RECEPTEURS DE ErbB DANS LE TRAITEMENT DU DIABETE
Abstract: front page image
(EN)The invention provides methods for treating pancreatic dysfunction, particularly diabetes, in mammals using ErbB receptor ligands, such as heregulin, betacellulin, and EGF. Methods of treating such conditions using anti-ErbB receptor agonist antibodies are further provided. The methods of the invention may be performed by direct administration of such therapeutically useful agents to mammals, or alternatively, by exposing certain pancreatic cell types to such agents $i(in vitro) and subsequently transplanting the treated cells to a mammal.
(FR)Cette invention concerne des méthodes de traitement du dysfonctionnement pancréatique, en particulier du diabète, chez les mammifères, au moyen de ligands récepteurs ErbB, tels que l'heréguline,la bétacelluline et EGF. L'invention concerne également des méthodes de traitement de ces pathologies au moyen d'anticorps agonistes anti-récepteur ErbB. Selon l'invention, on peut administrer directement ces agents utiles au plan thérapeutique à des mammifère, ou, en variante, exposer certains types de cellules pancréatiques à de tels agents $i(in vitro) et transplanter ultérieurement les cellules traitées dans un mammifères.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)